Shots:
- The P-III PEGASUS trial evaluates pemphigus (BTK inhibitor) vs PBO in 131 patients with newly diagnosed or relapsing mod. to sev. pemphigus in 19 countries globally
- The trial did not meet its 1EPs or 2EPs i.e., complete remission from 29 to 37wks. with minimal doses of CS (≤10/mg day). The safety profile remained consistent with previous results & no new safety signals were observed
- Rilzabrutinib is being evaluated in the P-III trial for immune thrombocytopenia, and the P-II study for autoimmune condition IgG4-related disease. Additionally, the company plans to start P-II studies for immunological diseases in 2021
Click here to read full press release/ article | Ref: Globe Newswire | Image: PharmaLive
The post Sanofi Provides Update on P-III PEGASUS Trial of Rilzabrutinib for the Treatment of Pemphigus first appeared on PharmaShots.
